GLP-1 coverage in Ontario

The Ontario Drug Benefit program lists Ozempic, Mounjaro and Rybelsus under Limited Use codes, which means coverage exists but only kicks in once a prescriber documents that a patient meets specific clinical criteria, generally a confirmed type 2 diabetes diagnosis and, often, evidence that other treatments have been tried first. Limited Use is different from a plain formulary listing: your pharmacy or prescriber has to submit the qualifying information before ODB will pay its share.

ODB itself is available to Ontarians 65 and older, residents in long-term care or receiving home care, and people on social assistance; OHIP+ separately covers those under 25 without private insurance. Outside those groups, working-age adults without coverage typically rely on employer plans, the Trillium Drug Program, or paying out of pocket.

None of Ontario's Limited Use listings for semaglutide or tirzepatide extend to weight-loss indications. The clinical criteria behind the Limited Use codes are built around diabetes management, so a prescription written for weight loss, whether for Wegovy, Saxenda, or an off-label use of a diabetes-indicated drug, falls outside what ODB will reimburse.

This is consistent with every other provincial plan in Canada: public coverage across the country currently tracks the diabetes indication only. Limited Use criteria are reviewed periodically, so it's worth checking the current Ontario Drug Benefit Formulary or asking your pharmacist if your situation may fall into a newly added category.

The Trillium Drug Program is designed for Ontarians whose prescription costs are high relative to household income, regardless of age, and it can apply to GLP-1 medications that also carry a Limited Use listing under ODB. Trillium works on a deductible tied to income, paid in quarterly instalments, and is worth applying for if drug costs are a significant household expense even with a job and no other public plan eligibility.

On the private side, roughly 31% of Canadian employer drug plans now offer some coverage for GLP-1s used for weight management, and Ontario's large base of workplace benefit plans makes this the most common path to weight-loss coverage in the province. Plan design varies significantly, so confirming details with your specific benefits provider is more reliable than assuming based on employer size or industry.

For Ontarians without applicable coverage, Costco Pharmacy has offered generic semaglutide at approximately $88/mo since Apotex and Dr. Reddy's launched Canadian generics in May 2026, and Costco's pharmacy counter doesn't require a membership. That price point sits well below brand alternatives.

Brand pricing at retail pharmacies generally runs $250 to $310/mo for Ozempic, $400 to $570/mo for Wegovy, $280 to $550/mo for Mounjaro, and $435 to $550/mo for Zepbound, before any insurance or manufacturer savings program is applied.

For Ontario residents facing a Limited Use denial or a gap before ODB approval comes through, ask whether generic semaglutide is a suitable and lower-cost alternative to brand Ozempic. If you have a documented diabetes diagnosis, make sure your prescriber has submitted the Limited Use paperwork correctly, since an incomplete submission is a common reason for an unexpected full-price bill at the pharmacy counter.

Manufacturer programs can also help with brand products: Novo Nordisk's Ozempic savings card and WegovyCare, and Eli Lilly's myMounjaro (about $185/mo with eligible coverage) and LillyConnect (Zepbound copay as low as $25/mo), though the lowest tiers of these programs generally require you to already hold private insurance. Compounded GLP-1 products are not legally sold in Canada and should not be treated as a cost-saving option.